Skip to main content

Table 1 Clinical characteristics of headache and associated symptoms after CGRP and placebo

From: Migraine induction with calcitonin gene-related peptide in patients from erenumab trials

Patient

Efficacy score (%)

Day

Time to peak headache (duration)

Headache characteristics

Associated symptoms

Mimics usual migraine

Migraine-like attack (onset)

Treatment (time)/efficacy

1

CM

50/75/0/25

CGRP

Placeboa

Spon

3 h (4 h)

80 min (NA)

Bilat/10/Throb+Pres/+

Bilat/6/Pres/M

Bilat/Throb/+

+/+/+

+/+/−

+/+/+

Yes

No

Yes (20min)

No

Sumatriptan 100 mg (6 h) / No

NR

2

EM

100/100/

100/100

CGRP

Placebo

Spon

2 h (NA)b

None

Bilat/10/Pres/+

−/+/−

Yes

Yes (20 min)

Sumatriptan 50 mg (2 h) / Yes

Right/Throb/+

+/+/−

3

EM

100/0/0/100

CGRP

Placebo

Spon

3 h (1 h)

30 min (1h)

Bilat/7/Throb/+

Bilat/3/Pres/M

Left/ Throb/+

+/+/+

−/+/−

+/+/+

Yes

No

Yes (70 min)

No

Sumatriptan 50 mg (3 h) / Yes, Treo (9 h) / NR

None

4

EM

100/50/0/100

CGRPc

Placebo

Spon

6 h (1 h)

10 h (NA)

Bilat/7/Throb+Pres/NR

Left/5/Throb/+

Left/Throb/+

+/+/+

−/−/+

+/+/+

NR

Yes

Yes (5 h)

No (NA)e

2 x KP (5 h) / No, Riza 10 mg (6 h) / NRd, KP (10 h) / Yes Riza + 2 x KP (10 h) / NRf

5

EM

0/25/0/0

CGRP

Placebo

Spon

3 h (1 h)

None

Bilat/5/Pres/+

Bilat/Throb/+

−/+/+

−/+/+

Yes

Yes (20 min)

Sumatriptan 100 mg (3 h) / Yes

6

EM

75/50/50/75

CGRP

Placebo

Spon

3 h (2 h)

9 h (2 h)

Right/4/Pres/−

Right/3/NR/-

Unilatg/Throb/+

−/+/−

−/+/−

+/+/+

Yes

Yes

Yes (2 h)

No (NA)

Zolmitriptan 2.5 mg (3 h) / Yes, 2 x Treo (6 h) / Yes

Treo (9 h) / NR

7

EM

75/75/0/75

CGRP

Placebo

Spon

1 h (10 min)

4 h (2 h)

Right/5/Throb/NR

Left/2/Pres/+

Unilat7/Throb/+

−/+/−

−/+/−

+/+/+

Yes

Yes

Yes (20 min)

No (NA)

2 x Treo (3 h) / Yes, Sumatriptan 50 mg (4 h) / Yes

None

8

EM

100/50/75/75

CGRP

Placebo

Spon

8 h (5 h)

50 min (10 min)

Left/9/Pres/+

Bilat/2/Pres/M

Left/Throb/+

+/+/+

−/+/−

+/+/+

Yes

No

Yes (2 h)

No (NA)

None

None

9

CM

75/0/75/75

CGRP

Placebo

Spon

4 h (5 h)

None

Right/2/Throb/+

ᅟ

Bilat+Unilath/Throb/+

−/−/−

ᅟ

+/+/+

Yes

No (NA)e

None

10

CM

100/0/25/100

CGRP

Placebo

Spon

None

None

Right/Throb/+

+/+/+

   

11

CM

0/0/0/0

CGRP

Placebo

Spon

50 min (10 min)

None

Bilat/5/Throb/M

Left/Throb/+

−/−/−

+/+/+

No

No (NA)

Panadol Extra + Ibuprofen 600 mg (2 h) / Yes

12

CM

50/25/0/25

CGRP

Placebo

Spon

6 h (1 h)

None

Right/9/Throb/+

Right/Throb/+

+/+/+

+/+/+

Yes

Yes (40 min)

2 x Treo + Paracetamol 1 g + Meto 10 mg (6 h) / Yes

13

CM

50/50/75/50

CGRP

Placebo

Spon

80 min (20 min)

7 h (1 h)

Right/5/Throb/+

Bilat/2/Pres/+

Right/Throb/+

−/+/+

−/−/−

+/+/+

Yes

No

Yes (60 min)

No (NA)

Sumatriptan 100 mg + Naproxen 500 mg (2 h) / Yes

None

  1. Efficacy score: Reduction in migraine days/reduction of the headache intensity/reduction in headache days/reduction in days of used rescue medication. Headache characteristics: Localization/intensity/quality/aggravation. Associated symptoms: Nausea/photophobia/phonophobia. The criteria for a migraine-like attack are described in ‘Methods’. Treatment efficacy: ≥ 50% decrease of headache intensity within 2 h
  2. Bilat Bilateral, Throb Throbbing, Pres Pressing, M Missing data, NR Not reported, CM Chronic migraine, EM Episodic migraine
  3. KP Codeine 30.6 mg + Paracetamol 500 mg, Panadol Extra Paracetamol 500 mg + Caffeine 65 mg, Treo Aspirin 500 mg + Caffeine 50 mg, Meto: Metoclopramide 10 mg, Riza: Rizatriptan 10 mg
  4. a2–12 h data not reported; b 3–4 h data not reported; c 2–12 h data not reported for aggravation and mimics usual migraine; d Sleep at 8–9 h, headache intensity score was 1 at 10 h; e Possible migraine-like attack; f 11–12 h data missing, but reported pain relief and sleep after medication intake; g Unilateral, no side preference; h Shifting between bilateral and unilateral (no side preference)
Back to article page

The Journal of Headache and Pain

ISSN: 1129-2377

Contact us